Mycovia Pharmaceuticals

Executive Summary

Mycovia Pharmaceuticals is a private biopharmaceutical company dedicated to developing innovative therapies for overlooked medical conditions, with a focus on antifungal and women's health. The company's lead product, VIVJOA (oteseconazole), received FDA approval in 2022 for the treatment of recurrent vulvovaginal candidiasis (RVVC), a chronic and underdiagnosed condition affecting millions of women worldwide. VIVJOA is the first and only FDA-approved oral therapy for RVVC, offering a novel mechanism of action as a CYP51 inhibitor that selectively targets fungal lanosterol 14α-demethylase. Mycovia's mission of treatment equality drives its efforts to address significant unmet needs, and the company continues to explore additional indications for oteseconazole, including potential use in other fungal infections. As a private entity, Mycovia has not disclosed detailed financials, but it has secured significant venture capital funding to support clinical development and commercialization. The company's proprietary technology and strong intellectual property position provide a competitive moat in the antifungal space, where resistance to existing azoles is an emerging challenge. With a small but focused pipeline, Mycovia aims to leverage its expertise to expand the therapeutic reach of its core asset while advancing earlier-stage candidates.

Upcoming Catalysts (preview)

• Q4 2026Potential label expansion of VIVJOA into new fungal indications (e.g., prevention of RVVC recurrence or treatment of other Candida infections)50% success
• Q2 2027Partnership or licensing deal for ex-U.S. commercialization of VIVJOA60% success
• Q3 2026Next financing round (Series C or later) to fund pipeline expansion80% success